Physician profile
Lara Mackintosh
NPI 1285262139
$1,204.33
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $499 · 2022: $705.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $234.27 | 2021-2022 | |
| Corcept Therapeutics | $217.98 | 2021-2022 | |
| Lilly USA, LLC | $120.65 | 2021-2022 | |
| Radius Health, INC. | $103.40 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $85.54 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $62.47 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.40 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $57.87 | 2021-2022 | |
| Amgen INC. | $56.43 | 2021-2022 | |
| Glaxosmithkline, LLC. | $30.98 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $27.07 | 2021 | |
| Mannkind Corporation | $24.98 | 2021 | |
| Horizon Therapeutics Plc | $23.43 | 2021 | |
| Amarin Pharma, INC. | $20.44 | 2021 | |
| Zealand Pharma US, INC. | $19.48 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.97 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.23 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.04 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $11.70 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lara Mackintosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.